Literature DB >> 19940171

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

Yanhua Ren1, John Whittard, Alejandro Higuera-Matas, Claudia V Morris, Yasmin L Hurd.   

Abstract

There remains debate regarding the impact of cannabis on neuropsychiatric disorders. Here, we examined the effects of cannabidiol (CBD), a nonpsychoactive constituent of cannabis, on heroin self-administration and drug-seeking behavior using an experimental rat model. CBD (5-20 mg/kg) did not alter stable intake of heroin self-administration, extinction behavior, or drug seeking induced by a heroin prime injection. Instead, it specifically attenuated heroin-seeking behavior reinstated by exposure to a conditioned stimulus cue. CBD had a protracted effect with significance evident after 24 h and even 2 weeks after administration. The behavioral effects were paralleled by neurobiological alterations in the glutamatergic and endocannabinoid systems. Discrete disturbances of AMPA GluR1 and cannabinoid type-1 receptor expression observed in the nucleus accumbens associated with stimulus cue-induced heroin seeking were normalized by CBD treatment. The findings highlight the unique contributions of distinct cannabis constituents to addiction vulnerability and suggest that CBD may be a potential treatment for heroin craving and relapse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19940171      PMCID: PMC2829756          DOI: 10.1523/JNEUROSCI.4291-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  34 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

Review 2.  The reinstatement model of drug relapse: history, methodology and major findings.

Authors:  Yavin Shaham; Uri Shalev; Lin Lu; Harriet de Wit; Jane Stewart
Journal:  Psychopharmacology (Berl)       Date:  2002-10-26       Impact factor: 4.530

3.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

4.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.

Authors:  Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-31       Impact factor: 5.067

5.  Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Authors:  A Thomas; G L Baillie; A M Phillips; R K Razdan; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

6.  Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats.

Authors:  Taco J De Vries; Judith R Homberg; Rob Binnekade; Halfdan Raasø; Anton N M Schoffelmeer
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

7.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

Review 8.  Endocannabinoid signaling as a synaptic circuit breaker in neurological disease.

Authors:  István Katona; Tamás F Freund
Journal:  Nat Med       Date:  2008-09-05       Impact factor: 53.440

9.  TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons.

Authors:  Ning Qin; Michael P Neeper; Yi Liu; Tasha L Hutchinson; Mary Lou Lubin; Christopher M Flores
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

Review 10.  Neural systems of reinforcement for drug addiction: from actions to habits to compulsion.

Authors:  Barry J Everitt; Trevor W Robbins
Journal:  Nat Neurosci       Date:  2005-11       Impact factor: 24.884

View more
  72 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Cannabinoid disposition in oral fluid after controlled smoked cannabis.

Authors:  Dayong Lee; David M Schwope; Garry Milman; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2012-01-24       Impact factor: 8.327

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

5.  No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.

Authors:  David H Epstein; Kenzie L Preston
Journal:  Am J Addict       Date:  2015-04-06

6.  High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.

Authors:  Maria Eugenia Socías; Evan Wood; Stephanie Lake; Seonaid Nolan; Nadia Fairbairn; Kanna Hayashi; Hennady P Shulha; Seagle Liu; Thomas Kerr; M-J Milloy
Journal:  Addiction       Date:  2018-09-20       Impact factor: 6.526

7.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

8.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

9.  The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada.

Authors:  Jenna Valleriani; Rebecca Haines-Saah; Rielle Capler; Ricky Bluthenthal; M Eugenia Socias; M J Milloy; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-04-11

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.